Media - published on 23 Jan 2018

Tracking Big Pharma’s Progress on AMR

Jim O’Neill, former chair of the AMR review, reports on the role of the Benchmark to make progress on the crucial public-health issue of AMR.

Jim O’Neill covers the launch of the new AMR Benchmark and the necessary data that will be used to make progress on the crucial public-health issue of AMR, and hopes that the many companies that have not been carrying their weight will finally feel compelled to act.



Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.